<DOC>
	<DOC>NCT01749865</DOC>
	<brief_summary>This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included. The patients will be randomized to group A (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer treatment after resection of HCC, and the randomize ratio will be 1:1.</brief_summary>
	<brief_title>CIK Treatment for HCC Patient Underwent Radical Resection</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Male or female patients over 18 years of age. Without any prior anticancer therapy. Patients who have a life expectancy of at least 12 weeks. Patients already had radical resection of HCC. Definition of radical resection in this study: All tumors were moved out, with a clean resection margin. Number of tumors less than 3. Without tumor invasion of the main trunk and first branch of the portal vein, or hepatic duct, or hepatic vein. No hepatic hilum lymphnode metastasis. No distance metastasis. Hepatocellular carcinoma with histological diagnose. No major postoperative complication. Patients who have an performance status of 0, or 1. Cirrhotic status of ChildPugh class A only. The following laboratory parameters: Patients who give written informed consent. Previous or concurrent cancer that is distinct in primary site or histology from HCC. History of cardiac disease. Active clinically serious infections ( over grade 2 National Cancer InstituteCommon Terminology Criteria for Adverse Events version 3.0) Known history of human immunodeficiency virus (HIV) infection Known Central Nervous System tumors including metastatic brain disease. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. History of organ allograft. Known or suspected allergy to the investigational agent or any agent given in association with this trial. Pregnant or breastfeeding patients. Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study. Excluded therapies and medications, previous and concomitant: Prior use of any anticancer treatment for HCC, eg. chemotherapy, radiotherapy. Antiviral treatment is allowed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>